BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Threshold Pharmaceuticals, Inc. 

170 Harbor Way
Suite 300
South San Francisco  California  94080-6108  U.S.A.
Phone: 650-474-8200 Fax: 650-474-2529


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical






 Company News
Threshold Pharmaceuticals, Inc. (THLD) Announces Phase 1/2 Interim Data Signaling Activity Of TH-302 Plus Bevacizumab (Avastin(R)) In Patients With Glioblastoma 11/19/2014 12:28:07 PM
Threshold Pharmaceuticals, Inc. (THLD) Announces Presentation And Webcast At The Stifel 2014 Healthcare Conference 11/11/2014 12:33:03 PM
Threshold Pharmaceuticals, Inc. (THLD) Receives FDA Fast Track Designation For TH-302 For The Treatment Of Previously Untreated Patients With Metastatic Or Locally Advanced Unresectable Soft Tissue Sarcoma 11/11/2014 10:51:41 AM
Threshold Pharmaceuticals, Inc. (THLD) Receives FDA Fast Track Designation For TH-302 For The Treatment Of Previously Untreated Patients With Metastatic Or Locally Advanced Unresectable Soft Tissue Sarcoma 11/11/2014 6:10:45 AM
SSF's Threshold Pharmaceuticals, Inc. (THLD) Snags Fast Track Status For Experimental Cancer Drug TH-302 11/11/2014 6:09:55 AM
Threshold Pharmaceuticals, Inc. (THLD) Announces New Phase 1/2 Data On TH-302 In Multiple Myeloma To Be Presented At The 2014 American Society of Hematology Annual Meeting 11/7/2014 12:13:02 PM
Threshold Pharmaceuticals, Inc. (THLD) Announces New Phase 1/2 Data On TH-302 In Glioblastoma To Be Presented At The 2014 SNO Annual Meeting 11/4/2014 1:05:46 PM
Threshold Pharmaceuticals, Inc. (THLD) Reports Third Quarter 2014 Financial And Operational Results 11/4/2014 1:00:06 PM
Threshold Pharmaceuticals, Inc. (THLD)' Partner Merck KGaA (MKGAF.PK), Darmstadt, Germany, Completes Target Enrollment In The TH-302 Phase 3 MAESTRO Study In Patients With Locally Advanced Or Metastatic Pancreatic Adenocarcinoma 11/4/2014 11:04:17 AM
Threshold Pharmaceuticals, Inc. (THLD) Announces Its Phase 3 Trial Of TH-302 In Patients With Advanced Soft Tissue Sarcoma Will Continue As Planned Following Protocol-Specified Interim Analysis 9/22/2014 11:10:42 AM
12345678910...